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0929-6646/Copyright ª 2014, ElsevierBackground/Purpose: Thymectomy may benefit patients with generalized myasthenia gravis
(MG) or myasthenia with thymomas. Currently, video-assisted (VA) thoracic surgery is popular
and plays an important role in thymectomy. We compared the clinical outcomes of VA thymec-
tomy with conventional transsternal (TS) approach to investigate the effectiveness of VA tech-
nology in the current era.
Methods: A retrospective review of our thymectomy results for patients with MG from 1998 to
2011 was conducted. A total of 83 consecutive patients were enrolled. According to the sur-
geons’ and patients’ preference, 39 patients received conventional TS thymectomy and 44
were operated on in a VA fashion. The results were categorized and analyzed according to
the Myasthenia Gravis Foundation of America (MGFA) postintervention statuses with some
modification.
Results: No obvious difference between conventional TS thymectomy and VA thymectomy was
noted regarding the remission statuses and the clinical outcomes by the modified MGFA score.
However, the patients who received VA thymectomy showed shorter intensive care unit (ICU)
stays (4.2  3.3 days vs. 2.3  1.5 days, p Z 0.001).
Conclusion: Compared with the conventional TS thymectomy, the VA approach is similarly
effective with shorter ICU stays.
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Myasthenia gravis (MG) is a systemic disease that results from
a loss of tolerance to self-antigens, which is caused by a loss
of thymus control and reduced T-lymphocyte tolerance.
Thymectomy may benefit patients with MG.1 This operation
can be performed through several different approaches,
including transcervical, transsternal (TS), subxyphoid, tho-
racotomy, and video-assisted (VA) thoracic surgery. An
extended thymectomy was advocated to achieve a better
response rate.2 Since then, there has been a persistent
concern regarding the completeness of the thymectomy by
theVA fashion,whichmight result in a compromisedoutcome
compared with that of a conventional TS approach. This
study was conducted to investigate the effectiveness of VA
thymectomy in the current era.
Patients and methods
Patient selection
Retrospective analysis of our thymectomy results, comparing
the VA and TS approach for patients aged > 15 years with
generalized type MG, from 1998 to 2011 was conducted. This
study was approved by the Institutional Review Board of
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City,
Taiwan. A total of 83 consecutive patients were enrolled.
According to the surgeons’ and patients’ preference, 39 pa-
tients received conventional TS thymectomy and 44 patients
were operated on in a VA fashion. The preoperative disease
status was classified on the basis of the Myasthenia Gravis
Foundation of America (MGFA) classification (Table 1).3,4
Surgical technique
General anesthesia was induced with cisatracurium
(0.05 mg/kg), followed by endotracheal tube intubationTable 1 Demographics of the two groups.
TS (n Z 39) VA (n Z 44) p
Sex (male:female) 6:7 3:8 0.07
Mean age (y) 42.9  14.3 37.0  12.1 0.04
Preoperative
disease statusa (%)
0.007
MG 1 1 (2.6) 9 (20.5)
MG 2 7 (17.9) 14 (31.8)
MG 3 25 (64.1) 15 (34.1)
MG 4 6 (15.4) 6 (13.6)
Total 39 44
Preoperative
body weight (kg)
65.2  17.1 66.7  18.2 0.12
Preoperative
intubation (%)
6 (15.4) 6 (13.6) 0.09
Preoperative
steroid use (%)
27 (69.2) 24 (54.5) 0.11
Follow-up period (mo) 79.3  13.6 31.5  6.4 0.002
MG Z myasthenia gravis; TS Z transsternal; VA Z video-
assisted.
a Myasthenia Gravis Foundation of America clinical
classification.and maintained with sevoflurane inhalation (2e4%) plus
fentanyl citrate and cisatracurium. Desflurane inhalation
was used occasionally as an adjuvant for the advantage of a
low blood-gas partition coefficient to achieve rapid offset
and recovery.5 The VA thymectomy was performed through
the right VA thoracoscopic approach. After a double-
luminal endotracheal tube general anesthesia, the patient
was placed in a 30 left semi-decubitus posture. A three-
port setting was adopted, with the working port at the
anterior axillary line of the fourth intercostal space, the
camera port at the middle axillary line of the fifth inter-
costal space, and the assist port positioned as needed. The
surgical techniques that we used were standard TS in the TS
group and the classic VA thoracic surgery technique in the
VA group, as described by Jaretzki et al.3 In both groups,
the grossly identifiable thymus and variable amounts of
anterior mediastinal fat were removed. The cervical ex-
tensions of the thymus were removed from below as well.
Postoperative care
The postoperative protocol for extubation was the same as
in ordinary patients who underwent thoracic surgery. Four
parameters including maximal inspiratory pressure <
20 cmH2O, maximal expiratory pressure > 20 cmH2O,
rapid shallow breathing index < 100 times/L, and cuff leak
volume < 110 mL were used to determine the extubation
timing. Since the operation day, the preoperative dosage of
anticholinesterase drugs and corticosteroids were
prescribed.
Statistical analysis
Statistical analysis was performed using SPSS version 13.0
(SPSS Inc., Chicago, IL, USA). Continuous variables acquired
from the clinical characteristics were expressed as the
mean  standard deviation and were compared using the
independent t test. Chi-square analysis was used for com-
parisons made between categorical variables. A two-tailed
probability value < 0.05 was considered statistically
significant.
Results
Patient characteristics
A total of 83 consecutive patients, consisting of 30 (36.1%)
men and 53 (63.9%) women, were enrolled in this study. TS
thymectomy was performed in 39 (47.0%) patients (TS
group) and VA thymectomy was performed in 44 (53.0%)
patients (VA group). The preoperative MGFA clinical clas-
sification ranged from class I to class IV. Class III was the
most common class, accounting for 40 patients (48.2%). The
statistical differences were not significant between the VA
and the TS groups regarding sex, body weight, incidences of
preoperative intubation, and incidences of preoperative
steroid use. However, the preoperative MGFA disease status
was earlier (pZ 0.007) and the age was younger (pZ 0.04)
in the VA group. The follow-up periods were 54.0  20.7
months for the overall population, 79.3  13.6 months for
Table 3 Postoperative results: Subgroup analysis, early
stage excluded.
TS (n Z 38) VA (n Z 35) p
Hospital stay (d) 14.8  11.7 15.9  4.1 0.96
Intensive care unit
stay (d)
4.2  3.3 2.6  1.5 0.01
Preoperative AchRAb
level
18.5  26.5 13.2  20.3 0.61
Postoperative AchRAb
level
11.8  18.1 12.0  17.1 0.64
Complication (%) 3a (7.9) 3b (8.6) 0.11
AchRAb Z acetylcholine receptor antibody; TS Z transsternal;
VA Z video-assisted.
a Superficial sternal wound infection: 1, reentry for hemo-
stasis: 2.
b Pneumonia: 1, extrapyramidal syndrome: 1, non-ST eleva-
tion myocardial infarction: 1.
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follow-up period was significantly shorter in the VA group
(p Z 0.002) because the VA approach has been adopted
since 2005 in our practice (Table 1).
Outcomes
In our series, the overall complete remission rate was 25.3%
(21/83) at the 2nd year. The 2nd year remission rate (better
than “improved” by MGFA postintervention status) was
84.1% (37/44) in the VA group and 89.7% (35/39) in the TS
group (p Z 0.15). There were no mortalities or intensive
care unit (ICU) readmissions in this study. The preoperative
acetylcholine receptor antibody level, postoperative
acetylcholine receptor antibody level, and complication
rates in the two groups showed no statistical difference.
The hospital and ICU stays were 14.7  5.6 days and
4.2  3.3 days, respectively, for the TS group and
11.6  5.7 days and 2.3  1.5 days, respectively, for the VA
group. The hospital stays showed no difference between
the two groups (p Z 0.49). However, the ICU stay was
significantly shorter in the VA group (p Z 0.001; Table 2).
Subgroup analysis
Because the preoperative MGFA disease class was earlier
(p Z 0.007) in the VA group, to eliminate possible bias
regarding the surgical benefit in early classes, a subgroup
analysis excluding the early class (MGFA Class I; 1 in the TS
group and 9 in the VA group) of MG patients was conducted.
In this analysis, the length of hospital stay, preoperative
acetylcholine receptor antibody level, postoperative
acetylcholine receptor antibody level, and complication
rates in these two groups showed no statistical difference.
However, the length of ICU stay was again significantly
shorter in the VA group (p Z 0.01; Table 3).
Modified MGFA score analysis
We also analyzed the outcomes based on the MGFA post-
intervention statuses with some modification for quantifi-
cation. This modified scoring system was designedTable 2 Postoperative results.
TS (n Z 39) VA (n Z 44) p
Hospital stay (d) 14.7  5.6 11.6  5.7 0.49
Intensive care unit
stay (d)
4.2  3.3 2.3  1.5 0.001
Preoperative AchRAb
level
18.2  9.0 21.6  12.7 0.42
Postoperative AchRAb
level
10.8  8.1 13.6  7.1 0.38
Complication (%) 3a (7.7) 3b (6.8) 0.11
AchRAb Z acetylcholine receptor antibody; TS Z transsternal;
VA Z video-assisted.
a Superficial sternal wound infection: 1, reentry for hemo-
stasis: 2.
b Pneumonia: 1, extrapyramidal syndrome: 1, non-ST eleva-
tion myocardial infarction: 1.according to the following 5-digit grading scale as: Grade 1
indicated complete remission, which meant medications
were no longer necessary; Grade 2 implied asymptomatic
status, which meant that the patients were symptom-free
with reduction of the medications; Grade 3 indicated
improvement, which meant that the symptoms improved
with the same medication regimen; Grade 4 indicated no
change; and Grade 5 indicated a worsening of symptoms
(Table 4). The short-term results at the 1st year and the 2nd
year by adopting this modified scoring system were
analyzed. There was no statistical difference identifiable
between the TS group and the VA group (pZ 0.39 at the 1st
year and p Z 0.36 at the 2nd year; Table 5).Discussion
Main findings
Our study confirmed the noninferior outcomes of the VA group
to the TS group. The length of hospital stay and the compli-
cation rateof theVAgroupwerecomparable to thoseof theTS
group or even better, although statistically nonsignificant.
Importantly, the VA approach did not compromise theTable 4 Correlations between the modified score and the
Myasthenia Gravis Foundation of America (MGFA) post-
intervention status.
Modified
score
Description MGFA postintervention status
1 CR CSR
2 Asymptomatic Pharmacologic remission
Minimal manifestation 0
3 Improved Minimal manifestation 1
Minimal manifestation 2
Minimal manifestation 3
4 Unchanged Unchanged
5 Worsened Worsened
CR Z complete remission; CSR Z complete surgical remission.
Table 5 Results calculated by the modified score in two
groups.
TS (n Z 39) VA (n Z 44) p
1-y results (%) 0.39
Modified score 1 8 (20.5) 5 (11.4)
Modified score 2 15 (38.5) 19 (43.2)
Modified score 3 11 (28.2) 9 (20.5)
Modified score 4 4 (10.3) 6 (13.6)
Modified score 5 1 (2.6) 5 (11.4)
2-y results (%) 0.36
Modified score 1 11 (28.2) 10 (22.7)
Modified score 2 18 (46.2) 15 (34.1)
Modified score 3 6 (15.4) 12 (27.3)
Modified score 4 2 (5.1) 1 (2.3)
Modified score 5 2 (5.1) 6 (13.6)
TS Z transsternal; VA Z video-assisted.
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VA group without any ICU readmission. The ICU readmission
rate has been reported as 1.93% in the population of diseases
of the nervous system and sense organs.6 In other words, the
shorter ICU stays without readmission might generally repre-
sent the careful patient evaluation and lowermedical costs in
the VA group of our study.
In our study, acute postoperative remission rates were
not dramatic. However, the complete remission and partial
remission rates increased during the first 2 years of follow-
up (Table 5). This observation was compatible with previous
reports, in which the surgical response improved progres-
sively.3,7 We agreed with the assumption advocated by
Tomulescu et al7 that this latency could be explained by the
constant use of corticosteroids. The steroid medication
dosage has to be progressively lowered, which means that a
longer time is needed to get total exclusion and achieve-
ment of complete stable remission with a high rate of
pharmacological remission.
Subgroup analysis
To eliminate the possible bias regarding the surgical benefit
in early classes, we also conducted a subgroup analysis, in
which patients of early class MG were excluded. After
excluding the early class MG patients in each group, the
length of hospital stay, pre- and postoperative acetylcho-
line receptor antibody levels in these two groups showed no
statistical differences. However, the length of ICU stay was
significantly shorter in the VA group (p Z 0.01). Impor-
tantly, the remission rates and the complication rates were
not significantly different between these two groups. These
observations suggest that thymectomy via the VA approach
would not compromise outcomes, even in patients of
advanced class MG.
Modified scoring system
The modified MGFA postintervention statuses scoring sys-
tem advocated in this study was useful to quantify the
outcomes of surgical results in a more simple fashion. Theshort-term results at the 1st year and the 2nd year by
adopting this modified scoring system showed that there
was no statistical difference between the two groups
(pZ 0.39 at the 1st year and pZ 0.36 at the 2nd year). This
observation suggested that the VA thymectomy was simi-
larly effective compared with the TS approach, regarding
the short- and mid-term remission.Acetylcholine receptor antibody
Nikolic et al8 reported that the clinical outcomes in pa-
tients with generalized MG may be relevant to the acetyl-
choline receptor antibody level. Therefore, we also
analyzed the pre- and postoperative antibody levels in both
VA and TS groups, to detect any possible correlation be-
tween the antibody levels, approach methods, and the
outcomes. The acetylcholine receptor antibody level was
checked at an out-patient clinic at stable status, usually
1e3 months after discharge. In our study, although the
postoperative antibody levels decreased significantly in
both groups, the antibody levels were not associated with
either the remission rates or the approach method. From
this preliminary clinico-biochemical correlation, again the
effectiveness of the VA thymectomy was supported to be
noninferior to the TS approach.Outcomes comparison
The clinical outcomes of our study were comparable with
those of recent reports. Meyer et al9 reported a post-
operative complete remission rate of 34.9% and indicated
that a better surgical result was obtained in the VA group.
Jurado et al10 reported that the VA group had less periop-
erative blood loss, and shorter ICU and hospital stays. The
complication rates of our series and these two series were
almost the same, ranging from 6% to 8%.Future perspectives
Surgical thymectomy has been justified in treating the
generalized type of MG. Meanwhile, medical treatment is
generally the first choice for the ocular type of MG.
Considering the feasibility and advantages of the minimally
invasive approach in the current era, VA thymectomy would
be an evolving therapeutic option even for the early classes
of MG. Similarly, the role of VA thymectomy for the treat-
ment of the ocular type of MG might evolve in the future.11
However, current guidelines prefer the medical treatment
for the ocular type of MG and there is no clinical evidence
indicating that the surgery improves the remission rate.12Limitations of the study
The natures of a retrospective, nonrandomized, small
population are the inevitable weakness of this study. A
larger, prospective, randomized, multicenter cooperative
study will certainly circumvent this predicament.
726 C.-M. Lo et al.Conclusion
From our study, we conclude that compared with the con-
ventional TS thymectomy, the VA approach is similarly effec-
tive, with the additional benefit of a shorter ICU unit stay.
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